drugset / Trial / NCT04848272
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Timeline
- Start
- 2021-08-09
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanadelumab | Monoclonal antibody | 30 mg | — |
| Subject | Lanadelumab | Monoclonal antibody | 100 mg | — |
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | — |